165 related articles for article (PubMed ID: 23934410)
1. [Gene expression analysis in breast cancer. A new diagnostic tool in pathology].
Denkert C
Pathologe; 2013 Sep; 34(5):413-8. PubMed ID: 23934410
[TBL] [Abstract][Full Text] [Related]
2. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Stöger H
Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
[No Abstract] [Full Text] [Related]
3. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
Gampenrieder SP
Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
[No Abstract] [Full Text] [Related]
4. Prognostic Factors for Luminal B-like Breast Cancer.
Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
[TBL] [Abstract][Full Text] [Related]
5. [Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].
Christgen M; Winkens W; Kreipe HH
Pathologe; 2014 Feb; 35(1):54-60. PubMed ID: 24414612
[TBL] [Abstract][Full Text] [Related]
6. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
7. [Beyond staging, typing and grading. New challenges in breast cancer pathology].
Kreipe HH; Ahrens P; Christgen M; Lehmann U; Länger F
Pathologe; 2010 Feb; 31(1):54-9. PubMed ID: 19949797
[TBL] [Abstract][Full Text] [Related]
8. Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
Park SJ; Lee MH; Kong SY; Song MK; Joo J; Kwon Y; Lee EG; Han JH; Sim SH; Jung SY; Lee S; Lee KS; Park IH; Lee ES
Breast Cancer Res Treat; 2018 Jul; 170(1):69-76. PubMed ID: 29516374
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
10. The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Dubsky PC; Singer CF; Egle D; Wette V; Petru E; Balic M; Pichler A; Greil R; Petzer AL; Bago-Horvath Z; Fesl C; Meek SM; Kronenwett R; Rudas M; Gnant M; Filipits M;
Eur J Cancer; 2020 Jul; 134():99-106. PubMed ID: 32502940
[TBL] [Abstract][Full Text] [Related]
11. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
12. [Translational research and diagnostics for breast cancer].
Kreipe HH
Pathologe; 2012 Nov; 33 Suppl 2():282-90. PubMed ID: 23064514
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor, human epidermal growth factor receptor-2, and Ki-67 status in primary breast cancer and corresponding recurrences or synchronous axillary lymph node metastases.
Yamanouchi K; Kuba S; Eguchi S
Surg Today; 2020 Jul; 50(7):657-663. PubMed ID: 31190183
[TBL] [Abstract][Full Text] [Related]
14. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
[TBL] [Abstract][Full Text] [Related]
16. Predicting endocrine therapy responsiveness in breast cancer.
Ma CX; Sanchez CG; Ellis MJ
Oncology (Williston Park); 2009 Feb; 23(2):133-42. PubMed ID: 19323294
[TBL] [Abstract][Full Text] [Related]
17. EndoPredict
Almstedt K; Mendoza S; Otto M; Battista MJ; Steetskamp J; Heimes AS; Krajnak S; Poplawski A; Gerhold-Ay A; Hasenburg A; Denkert C; Schmidt M
Breast Cancer Res Treat; 2020 Jul; 182(1):137-146. PubMed ID: 32436145
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
Varga Z; Sinn P; Fritzsche F; von Hochstetter A; Noske A; Schraml P; Tausch C; Trojan A; Moch H
PLoS One; 2013; 8(3):e58483. PubMed ID: 23505515
[TBL] [Abstract][Full Text] [Related]
19. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
[TBL] [Abstract][Full Text] [Related]
20. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Fernandez-Martinez A; Pascual T; Perrone G; Morales S; de la Haba J; González-Rivera M; Galván P; Zalfa F; Amato M; Gonzalez L; Prats M; Rojo F; Manso L; Paré L; Alonso I; Albanell J; Vivancos A; González A; Matito J; González S; Fernandez P; Adamo B; Muñoz M; Viladot M; Font C; Aya F; Vidal M; Caballero R; Carrasco E; Altomare V; Tonini G; Prat A; Martin M
Oncotarget; 2017 Mar; 8(13):21930-21937. PubMed ID: 28423537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
